We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00393354
First Posted: October 27, 2006
Last Update Posted: November 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
October 26, 2006
October 27, 2006
November 30, 2015
April 2000
November 2000   (Final data collection date for primary outcome measure)
Low back pain intensity scale (0-100 mm VAS) over 4 weeks compared to placebo
Same as current
Complete list of historical versions of study NCT00393354 on ClinicalTrials.gov Archive Site
Low back pain intensity scale (0-100 mm VAS) over 12 weeks compared to placebo
Same as current
Not Provided
Not Provided
 
Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)
A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain
Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Recurrent Low Back Pain
  • Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
  • Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
325
November 2000
November 2000   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Low back pain for previous 3 months and majority of days in last month
  • Regular use of acetaminophen or NSAID to treat low back pain in past month
  • Judged to be in otherwise good health

Exclusion Criteria:

  • Low back pain that is due to secondary causes
  • Radicular/myelopathic pain
  • Surgery for low back pain within the past 6 months
  • Active lawsuit or claim pertaining to their low back pain
  • Disease that may confound the results of the study or pose risk to the patients
  • Corticosteroid use in past month
  • Previous participation in MK0663 study
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00393354
0663-041
2006_548
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP